Biological Phenotypes of Heart Failure With Preserved Ejection Fraction

Journal of the American College of Cardiology

Volumn 70, Issue 17, 2017, Pages 2186-2200

  Lewis, Gavin A ^a,b   Schelbert, Erik B ^c,d   Williams, Simon G ^b   Cunnington, Colin ^a,b   Ahmed, Fozia ^a,b   McDonagh, Theresa A ^e   Miller, Christopher A ^a,b,f  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

diastolic dysfunction; ejection fraction; heart failure; heart failure with preserved ejection fraction; myocardial fibrosis; titin

Indexed keywords

EMPAGLIFLOZIN;

CALCIUM HOMEOSTASIS; CARDIAC MUSCLE CELL; CAUSAL ATTRIBUTION; CELL FUNCTION; CELL STRUCTURE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENERGY TRANSFER; EXTRACELLULAR MATRIX; FUNCTIONAL ASSESSMENT; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; INTERVENTION STUDY; LUNG BLOOD VESSEL; MICROVASCULARIZATION; MORPHOLOGY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SURVIVAL RATE; BLOOD VESSEL; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; KIDNEY DISEASE; LUNG DISEASE; PATHOLOGY; PULMONARY ARTERY;

BLOOD VESSELS; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; KIDNEY DISEASES; LUNG DISEASES; OBESITY; PHENOTYPE; PULMONARY ARTERY; STROKE VOLUME;

EID: 85032144648     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.09.006     Document Type: Review

References (127)

1. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 18 (2016), 891–975.
2. Senni, M., Paulus, W.J., Gavazzi, A., et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 35 (2014), 2797–2815.
3. Butler, J., Fonarow, G.C., Zile, M.R., et al. Developing therapies for heart failure with preserved ejection fraction. J Am Coll Cardiol HF 2 (2014), 97–112.
4. Shah, S.J., Kitzman, D.W., Borlaug, B.A., et al. Phenotype-specific treatment of heart failure with preserved ejection fraction. Circulation 134 (2016), 73–90.
5. Zile, M.R., Gottdiener, J.S., Hetzel, S.J., et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124 (2011), 2491–2501.
6. Katz, D.H., Beussink, L., Sauer, A.J., et al. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol 112 (2013), 1158–1164.
7. Shah, A.M., Shah, S.J., Anand, I.S., et al. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail 7 (2014), 104–115.
8. Lam, C.S., Roger, V.L., Rodeheffer, R.J., et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115 (2007), 1982–1990.
9. Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the TOPCAT Trial. Circ Heart Fail 7 (2014), 740–751.
10. Persson, H., Lonn, E., Edner, M., et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 49 (2007), 687–694.
11. Cuspidi, C., Rescaldani, M., Sala, C., Prevalence of echocardiographic left-atrial enlargement in hypertension. Am J Hypertens 26 (2013), 456–464.
12. Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
13. Massie, B.M., Carson, P.E., McMurray, J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
14. Yusuf, S., Pfeffer, M.A., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
15. Westermann, D., Kasner, M., Steendijk, P., et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 117 (2008), 2051–2060.
16. Shah, A.M., Claggett, B., Kitzman, D., et al. Contemporary assessment of left ventricular diastolic function in older adults. Circulation 135 (2017), 426–439.
17. Tschope, C., Paulus, W.J., Is echocardiographic evaluation of diastolic function useful in determining clinical care?. Circulation 120 (2009), 810–820.
18. Freed, B.H., Daruwalla, V., Cheng, J.Y., et al. Prognostic utility and clinical significance of cardiac mechanics in heart failure with preserved ejection fraction: importance of left atrial strain. Circ Cardiovasc Imaging, 9, 2016, e003754.
19. Solomon, S.D., Claggett, B., Lewis, E.F., et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37 (2016), 455–462.
20. Borbely, A., van der Velden, J., Papp, Z., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111 (2005), 774–781.
21. Zile, M.R., Baicu, C.F., Ikonomidis, J.S., et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation 131 (2015), 1247–1259.
22. van Heerebeek, L., Borbely, A., Niessen, H.W., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 (2006), 1966–1973.
23. Linke, W.A., Hamdani, N., Gigantic business: titin properties and function through thick and thin. Circ Res 114 (2014), 1052–1068.
24. Methawasin, M., Strom, J.G., Slater, R.E., et al. Experimentally increasing the compliance of titin through RBM20 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction. Circulation 134 (2016), 1085–1099.
25. LeWinter, M.M., Granzier, H.L., Cardiac titin and heart disease. J Cardiovasc Pharmacol 63 (2014), 207–212.
26. Borbely, A., Falcao-Pires, I., van Heerebeek, L., et al. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 104 (2009), 780–786.
27. Hamdani, N., Franssen, C., Lourenco, A., et al. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail 6 (2013), 1239–1249.
28. Bishu, K., Hamdani, N., Mohammed, S.F., et al. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124 (2011), 2882–2891.
29. Fukuda, N., Wu, Y., Nair, P., Granzier, H.L., Phosphorylation of titin modulates passive stiffness of cardiac muscle in a titin isoform-dependent manner. J Gen Physiol 125 (2005), 257–271.
30. van Heerebeek, L., Hamdani, N., Falcao-Pires, I., et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126 (2012), 830–839.
31. Solomon, S.D., Zile, M., Pieske, B., et al., for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction. Lancet 380 (2012), 1387–1395.
32. Adeniran, I., MacIver, D.H., Hancox, J.C., et al. Abnormal calcium homeostasis in heart failure with preserved ejection fraction is related to both reduced contractile function and incomplete relaxation. Front Physiol, 6, 2015, 78.
33. Selby, D.E., Palmer, B.M., LeWinter, M.M., et al. Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 58 (2011), 147–154.
34. Lacombe, V.A., Viatchenko-Karpinski, S., Terentyev, D., et al. Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 293 (2007), R1787–R1797.
35. Zile, M.R., Gaasch, W.H., Abnormal calcium homeostasis: one mechanism in diastolic heart failure. J Am Coll Cardiol 58 (2011), 155–157.
36. Komajda, M., Isnard, R., Cohen-Solal, A., et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY trial. Eur J Heart Fail, 2017 Apr 30 [E-pub ahead of print].
37. Kosmala, W., Holland, D.J., Rojek, A., et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol 62 (2013), 1330–1338.
38. Pal, N., Sivaswamy, N., Mahmod, M., et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132 (2015), 1719–1725.
39. Sossalla, S., Wagner, S., Rasenack, E.C., et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts. J Mol Cell Cardiol 45 (2008), 32–43.
40. Jacobshagen, C., Belardinelli, L., Hasenfuss, G., et al. Ranolazine for the treatment of heart failure with preserved ejection fraction. Clin Cardiol 34 (2011), 426–432.
41. Primessnig, U., Schonleitner, P., Holl, A., et al. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction. Eur J Heart Fail 18 (2016), 987–997.
42. Kamimura, D., Ohtani, T., Sakata, Y., et al. Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J 33 (2012), 1408–1416.
43. Sabbah, H.N., Sharov, V.G., Lesch, M., Goldstein, S., Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 147 (1995), 29–34.
44. Phan, T.T., Abozguia, K., Nallur Shivu, G., et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol 54 (2009), 402–409.
45. Lamb, H.J., Beyerbacht, H.P., van der Laarse, A., et al. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99 (1999), 2261–2267.
46. Hunter, W.G., Kelly, J.P., McGarrah, R.W., et al. Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction. J Am Heart Assoc, 5, 2016.
47. Beadle, R.M., Williams, L.K., Kuehl, M., et al. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy. J Am Coll Cardiol HF 3 (2015), 202–211.
48. Abozguia, K., Elliott, P., McKenna, W., et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122 (2010), 1562–1569.
49. Fragasso, G., Perseghin, G., De Cobelli, F., et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27 (2006), 942–948.
50. Diez, J., Querejeta, R., Lopez, B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002), 2512–2517.
51. Zile, M.R., Baicu, C.F., Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res 6 (2013), 501–515.
52. Kasner, M., Westermann, D., Lopez, B., et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 57 (2011), 977–985.
53. Duca, F., Kammerlander, A.A., Zotter-Tufaro, C., et al. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction. Circ Cardiovasc Imaging, 9, 2016, e005277.
54. Rommel, K.P., von Roeder, M., Latuscynski, K., et al. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 67 (2016), 1815–1825.
55. Krum, H., Elsik, M., Schneider, H.G., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 4 (2011), 561–568.
56. Ahmad, T., Fiuzat, M., Felker, G.M., O'Connor, C., Novel biomarkers in chronic heart failure. Nat Rev Cardiol 9 (2012), 347–359.
57. Schelbert, E.B., Fridman, Y., Wong, T.C., et al. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome. JAMA Cardiol 2 (2017), 995–1006.
58. Schelbert, E.B., Wong, T.C., Gheorghiade, M., Think small and examine the constituents of left ventricular hypertrophy and heart failure. J Am Heart Assoc, 4, 2015, e002491.
59. Mohammed, S.F., Hussain, S., Mirzoyev, S.A., et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
60. Brilla, C.G., Funck, R.C., Rupp, H., Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000), 1388–1393.
61. Izawa, H., Murohara, T., Nagata, K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy. Circulation 112 (2005), 2940–2945.
62. Deswal, A., Richardson, P., Bozkurt, B., Mann, D.L., Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail 17 (2011), 634–642.
63. Cleland, J.G.F., Tendera, M., Adamus, J., et al. The perindopril in elderly people with chronic heart failure study. Eur Heart J 27 (2006), 2338–2345.
64. von Lueder, T.G., Wang, B.H., Kompa, A.R., et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 8 (2015), 71–78.
65. Lopez, B., Querejeta, R., Gonzalez, A., et al. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure. Hypertension 60 (2012), 677–683.
66. TORAFIC Investigators Group. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure. Clin Ther 33 (2011), 1204–1213.e3.
67. Yang, J., Savvatis, K., Kang, J.S., et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun, 7, 2016, 13710.
68. Meissner, E.G., McLaughlin, M., Matthews, L., et al. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults. Liver Int 36 (2016), 1783–1792.
69. Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
70. Kalogeropoulos, A., Georgiopoulou, V., Psaty, B.M., et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC study. J Am Coll Cardiol 55 (2010), 2129–2137.
71. Westermann, D., Lindner, D., Kasner, M., et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4 (2011), 44–52.
72. Franssen, C., Chen, S., Unger, A., et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. J Am Coll Cardiol HF 4 (2016), 312–324.
73. Goligorsky, M.S., Microvascular rarefaction: the decline and fall of blood vessels. Organogenesis 6 (2010), 1–10.
74. Srivaratharajah, K., Coutinho, T., deKemp, R., et al. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail, 9, 2016.
75. Kato, S., Saito, N., Kirigaya, H., et al. Impairment of coronary flow reserve evaluated by phase contrast cine-magnetic resonance imaging in patients with heart failure with preserved ejection fraction. J Am Heart Assoc, 5, 2016, e002649.
76. van Empel, V.P., Mariani, J., Borlaug, B.A., et al. Impaired myocardial oxygen availability contributes to abnormal exercise hemodynamics in heart failure with preserved ejection fraction. J Am Heart Assoc, 3, 2014, e001293.
77. Tavazzi, L., Maggioni, A.P., Marchioli, R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial). Lancet 372 (2008), 1231–1239.
78. Redfield, M.M., Chen, H.H., Borlaug, B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction. JAMA 309 (2013), 1268–1277.
79. Kjekshus, J., Apetrei, E., Barrios, V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007), 2248–2261.
80. Weber, T., Auer, J., O'Rourke, M.F., et al. Prolonged mechanical systole and increased arterial wave reflections in diastolic dysfunction. Heart 92 (2006), 1616–1622.
81. Desai, A.S., Mitchell, G.F., Fang, J.C., et al. Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail 15 (2009), 658–664.
82. Borlaug, B.A., Melenovsky, V., Redfield, M.M., et al. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol 50 (2007), 1570–1577.
83. Weber, T., O'Rourke, M.F., Ammer, M., et al. Arterial stiffness and arterial wave reflections are associated with systolic and diastolic function in patients with normal ejection fraction. Am J Hypertens 21 (2008), 1194–1202.
84. Kitzman, D.W., Herrington, D.M., Brubaker, P.H., et al. Carotid arterial stiffness and its relationship to exercise intolerance in older patients with heart failure and preserved ejection fraction. Hypertension 61 (2013), 112–119.
85. Hundley, W.G., Kitzman, D.W., Morgan, T.M., et al. Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 38 (2001), 796–802.
86. Kobayashi, S., Yano, M., Kohno, M., et al. Influence of aortic impedance on the development of pressure-overload left ventricular hypertrophy in rats. Circulation 94 (1996), 3362–3368.
87. Stokes, G.S., Ryan, M., Brnabic, A., et al. A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension. J Hypertens 17 (1999), 1767–1773.
88. Zamani, P., Akers, S., Soto-Calderon, H., et al. Isosorbide dinitrate, with or without hydralazine, does not reduce wave reflections, left ventricular hypertrophy, or myocardial fibrosis in patients with heart failure with preserved ejection fraction. J Am Heart Assoc, 6, 2017, e004262.
89. Redfield, M.M., Anstrom, K.J., Levine, J.A., et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 373 (2015), 2314–2324.
90. Chirinos, J.A., Zamani, P., The Nitrate-nitrite-NO pathway and its implications for heart failure and preserved ejection fraction. Curr Heart Fail Rep 13 (2016), 47–59.
91. Borlaug, B.A., Koepp, K.E., Melenovsky, V., Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction. J Am Coll Cardiol 66 (2015), 1672–1682.
92. Zamani, P., Tan, V., Soto-Calderon, H., et al. Pharmacokinetics and pharmacodynamics of inorganic nitrate in heart failure with preserved ejection fraction. Circ Res 120 (2017), 1151–1161.
93. Zamani, P., Rabat, D., Shiva-Kumar, P., et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 131 (2015), 371–380.
94. Kitzman, D.W., Hundley, W.G., Brubaker, P.H., et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction. Circ Heart Fail 3 (2010), 477–485.
95. Kitzman, D.W., Nicklas, B., Kraus, W.E., et al. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 306 (2014), H1364–H1370.
96. Bhella, P.S., Prasad, A., Heinicke, K., et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail 13 (2011), 1296–1304.
97. Haykowsky, M.J., Brubaker, P.H., John, J.M., et al. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol 58 (2011), 265–274.
98. Lam, C.S., Roger, V.L., Rodeheffer, R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53 (2009), 1119–1126.
99. Gerges, M., Gerges, C., Pistritto, A.M., et al. Pulmonary hypertension in heart failure. Epidemiology, right ventricular function, and survival. Am J Respir Crit Care Med 192 (2015), 1234–1246.
100. Guazzi, M., Vicenzi, M., Arena, R., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124 (2011), 164–174.
101. Hoendermis, E.S., Liu, L.C., Hummel, Y.M., et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur Heart J 36 (2015), 2565–2573.
102. Bonderman, D., Pretsch, I., Steringer-Mascherbauer, R., et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure. Chest 146 (2014), 1274–1285.
103. Kenchaiah, S., Evans, J.C., Levy, D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002), 305–313.
104. Ebong, I.A., Goff, D.C. Jr., Rodriguez, C.J., et al. The relationship between measures of obesity and incident heart failure: the multi-ethnic study of atherosclerosis. Obesity (Silver Spring) 21 (2013), 1915–1922.
105. Sundström, J., Bruze, G., Ottosson, J., et al. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 135 (2017), 1577–1585.
106. Aune, D., Sen, A., Norat, T., et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 133 (2016), 639–649.
107. Owan, T.E., Hodge, D.O., Herges, R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
108. Obokata, M., Reddy, Y.N.V., Pislaru, S.V., et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136 (2017), 6–19.
109. Aggarwal, R., Harling, L., Efthimiou, E., Darzi, A., Athanasiou, T., Ashrafian, H., The effects of bariatric surgery on cardiac structure and function: a systematic review of cardiac imaging outcomes. Obes Surg 26 (2015), 1030–1040.
110. Lainscak, M., Anker, S.D., Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges. ESC Heart Fail 2 (2015), 103–107.
111. Agarwal, S.K., Heiss, G., Barr, R.G., et al. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 14 (2012), 414–422.
112. Lam, C.S., Lyass, A., Kraigher-Krainer, E., et al. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 124 (2011), 24–30.
113. Barr, R.G., Bluemke, D.A., Ahmed, F.S., et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 362 (2010), 217–227.
114. Stahrenberg, R., Duvinage, A., Mende, M., et al. Determinants of submaximal exercise capacity in patients at risk for heart failure with preserved ejection fraction-results from the DIAST-CHF study. ESC Heart Fail 2 (2015), 76–84.
115. Mentz, R.J., Kelly, J.P., von Lueder, T.G., et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 64 (2014), 2281–2293.
116. Ather, S., Chan, W., Bozkurt, B., et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59 (2012), 998–1005.
117. Damman, K., Valente, M.A., Voors, A.A., O'Connor, C.M., van Veldhuisen, D.J., Hillege, H.L., Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35 (2014), 455–469.
118. Lopez-Sanchez, M., Munoz-Esquerre, M., Huertas, D., et al. Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction. Clin Respir J, 2015 Dec 10 [E-pub ahead of print].
119. Cavalera, M., Wang, J., Frangogiannis, N.G., Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 164 (2014), 323–335.
120. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
121. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37 (2016), 1526–1534.
122. Butler, J., Hamo, C.E., Filippatos, G., et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail, 2017 Aug 24 [E-pub ahead of print].
123. Komajda, M., Lam, C.S., Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35 (2014), 1022–1032.
124. Shah, S.J., Katz, D.H., Selvaraj, S., et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131 (2015), 269–279.
125. Horn, M.A., Trafford, A.W., Aging and the cardiac collagen matrix: novel mediators of fibrotic remodelling. J Mol Cell Cardiol 93 (2016), 175–185.
126. Anand, I.S., Rector, T.S., Cleland, J.G., et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4 (2011), 569–577.
127. Anand, I.S., Claggett, B., Liu, J., et al. Interaction between spironolactone and natriuretic peptides in patients with heart failure and preserved ejection fraction: from the TOPCAT trial. JACC Heart Fail 5 (2017), 241–252.